Evidence map›Paper›PMID 34194720›Full record

ArticleJournal of osteoporosis2021

A  Phase IV Study of the Safety and Efficacy of CinnoPar

Ahmadreza Jamshidi, Farhad Gharibdoost, Sima Sedighi, Asghar Hajiabbasi, Amir-Hossein Salari, Alireza Khabbazi, Peyman Mottaghi, Ahmad Tahammoli Roudsari, Mehrdad Aghaei, Irandokht Shenavar Masooleh and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of osteoporosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Ahmadreza JamshidiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0464-8715
Farhad GharibdoostRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0324-2609
Sima SedighiBones, Joints, and Connective Tissue Research Center, Golestan University of Medical Sciences, Gorgan, Iran.ORCID https://orcid.org/0000-0002-0328-0728
Asghar HajiabbasiGuilan Rheumatology Research Center, Department of Rheumatology, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.ORCID https://orcid.org/0000-0001-7892-7664
Amir-Hossein SalariRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alireza KhabbaziConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-9482-6967
Peyman MottaghiDepartment of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-9810-4136
Ahmad Tahammoli RoudsariDepartment of Internal Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-5431-4836
Mehrdad AghaeiGolestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.ORCID https://orcid.org/0000-0002-0143-7306
Irandokht Shenavar MasoolehGuilan Rheumatology Research Center, Department of Rheumatology, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.ORCID https://orcid.org/0000-0002-3967-7022
Araz SabzvariCinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Nassim AnjidaniMedical Department, Orchid Pharmed Company, Tehran, Iran.ORCID https://orcid.org/0000-0001-7247-6743
Tehran University of Medical Sciences · IRGolestan University · IRGuilan University of Medical Sciences · IRBiotechnology Research Center · IRHamedan University of Medical Sciences · IRIsfahan University of Medical Sciences · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar

Identifiers

PMID34194720
PMCPMC8184341
OpenAlexW3167063469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.